Category Archives: Immunology

Latex detection dogs help people with allergy return to normal life – TODAY

Ellen Heilman has been living with a latex allergy since she was 5 a worsening sensitivity that can leave her struggling to breathe if theres a rubber band, balloon or latex glove nearby.

It got to the point where I really couldnt leave my house safely. At 21 years old, that was not cool, Heilman, a graduate student who is now 22 and lives in Odenton, Maryland, told TODAY.

I used to be on high alert all the time, always looking over my shoulder: Where are the balloons? Where are the gloves? Im not safe anywhere. Now, I know that he has my back, that we are a team and that together, well find it and well be safe.

He is Francis, a 3-year-old service dog trained to detect natural rubber latex and alert Heilman to its presence. The black lab goes with her everywhere, from Target to class, sniffing for the allergen as they enter the building or room.

His highly-sensitive nose can recognize latex through cabinet seams and under doors. If Francis detects it, he sits down in a distinct way that Heilman recognizes right away. Depending on the situation, the latex object is either taken away or Heilman leaves the area.

I went from being able to go nowhere to being pretty much able to go anywhere, she said. Its a huge difference it makes things so much better for me.

Dogs have been trained to help people with peanut allergies for years. There are even gluten-sniffing canines.

But their role in latex detection has been rare, though its definitely on the rise, said Ciara Gavin, founder of Allergen Detection Service Dogs, a facility in Colorado Springs, Colorado, that provided Heilmans canine. The business used to focus mostly on training dogs to detect peanuts.

Lately, Ive had a lot of calls about latex detection, Gavin said. People are finding out more about it. Instead of living in a hopeless kind of situation where they feel like, I cant go anywhere because of this allergy, theyre finding out there might be hope.

Trending stories,celebrity news and all the best of TODAY.

She placed her first latex detection dog two years ago. Now, one or two of the four dogs total she places each year are latex detection dogs, usually black labs.

Fewer than 1% of people in the U.S. have a latex allergy, according to the Asthma and Allergy Foundation of America. But that proportion rises to 8-12% among health care workers who are exposed to latex gloves or medical products containing the substance, the Occupational Safety and Health Administration noted.

People can react when they breathe in latex fibers in the air or touch latex in objects such as condoms, handbags, athletic shoes, tires, waistbands, rubber toys, baby bottles and pacifiers.

Symptoms can include hives, itching, wheezing, a runny nose, chest tightness and difficulty breathing. They can be part of anaphylaxis, a severe, whole-body life-threatening allergic reaction.

The allergy usually develops after many previous exposures to latex, according to the American College of Allergy, Asthma & Immunology. Studies have called it a growing disease that can occur at any age.

Amy Crawford, 47, first found out she had a latex allergy last year when she was blowing up a balloons for a childrens party.

The next thing I know, I cant breathe, my face is just swollen and red, and covered in bumps and hives. I ended up being taken to the emergency room, Crawford, a middle school teacher in Humble, Texas, recalled.

They told me: You have a latex allergy. Go see a doctor. Get a [medical alert] bracelet.

Her only clue before that incident was a sensitivity to avocados, strawberries and kiwis. People with a latex allergy can also be allergic to foods that share certain proteins with latex, according to the American Academy of Allergy, Asthma & Immunology.

Crawford has now been to the emergency room six times in less than a year. Exposure to latex, whether airborne or via skin contact, can cause her throat to close up to the point where she cant swallow and has trouble breathing.

She carries an EpiPen with her everywhere she goes and wears a mask as a precaution. Crawford doesnt travel anywhere and cant take her two sons, ages 8 and 14, to birthday parties anymore.

Shes crowdfunding for a latex detection dog, which will cost about $17,000.

Im looking forward to just being able to just walk into a room, because I cant do that now. I have to peak in and look: Are there balloons? Is there anything that could affect me? Crawford said. My kids are really suffering because theyre terrified all the time.

It takes six months for a dog to be trained, Gavin said. The new owners and their canines then spend two weeks getting to know each other under the supervision of a trainer to make sure they understand each others signals.

The dogs are taught to sit and stare at the source of the latex. Theyre at least 95% accurate, but that estimate can depend on air currents, the size of the item and where its located, Gavin noted.

Heilman and her service dog Francis bonded the minute they met, she recalled.

At this point, it is kind of like we are one being. He uses his nose, I use my eyes and together we make sure I am safe, she said.

Continued here:
Latex detection dogs help people with allergy return to normal life - TODAY

Bicycle and Genentech Forge Immuno-Oncology Collaboration Worth up to $1.7 Billion – BioSpace

Shares of U.K.-based Bicycle Therapeutics are climbing this morning after the company announced it entered into a strategic immuno-oncology collaboration with Genentech to discover, develop and commercialize novelBicycle-based immuno-oncology therapies.

The collaboration has a value of up to $1.7 billion if all milestones are hit. Under terms of the agreement, Bicycle will receive an upfront payment of $30 million to focus its proprietary bicyclic peptides platform on a wide range of immuno-oncology targets. The U.K. companys proprietary discovery platform allows for rapid screening of novel targets to identifyBicyclesand the ability to readily conjugate these together to create novel molecules that may overcome the potential limitations of other modalities. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, which makes Bicycles attractive candidates for drug development, the company said.

Genentech, a Roche company, brings to the collaboration its knowledge of immuno-oncology drug discovery and emerging target biology, as well as its development and commercialization expertise, Bicycle said this morning.

Bicycle Chief Executive Officer Kevin Lee said the collaboration with Genentech recognizes the potential of his companys differentiated technology, which allows it to specifically direct immune cell stimulators and other payloads to tumors in a highly targeted manner. Additionally, Lee said, the flexibility of the companys platform will enable the rapid exploration of structure-activity relationships to fully optimize candidate molecules.

In its announcement, Bicycle did not identify the cancer targets it will focus on in its collaboration with Genentech. The company only said it will collaborate with Genentech on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.

James Sabry, Roches head of Pharma Partnering, said Bicycles represent a novel therapeutic modality that have shown promise as modulators of several types of tumor-killing immune cells.

By leveraging Genentechs deep understanding of cancer immunology and Bicycles technological expertise, we hope to create a new wave of immunotherapy options to expand the population of patients who could potentially benefit from this powerful treatment paradigm, Sabry said in a statement.

Bicycle will be responsible for discovery research and early pre-clinical development up to candidate selection and Genentech will be responsible for further development and commercialization upon the selection of candidates. None of Bicycles wholly-owned oncology pipeline, including its immuno-oncology candidates, are included in the collaboration, the company noted. Bicycles lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP. BT1718 is being investigated in an ongoing Phase I/IIa clinical. The company is also investigating BT5528, a BTC targeting tumor antigen EphA2, in patients with advanced solid tumors associated with EphA2 expression.

The collaboration with Genentech follows a partnership with Cancer Research UK to develop BT7401, a multivalent Bicycle CD137 agonist, through a Phase IIa clinical study.

Continued here:
Bicycle and Genentech Forge Immuno-Oncology Collaboration Worth up to $1.7 Billion - BioSpace

Meet the Company That Just Might Prevent a Global Recession – Motley Fool

You might think it's crazy to even remotely suggest that one company could singlehandedly thwart the onset of a global economic recession. But make no mistake -- that's exactly what I'm doing.

I think the odds are pretty high right now that a recession could be on the way. The coronavirus outbreak that started in China has now spread to many countries around the world. It's already making a significant financial impact. There's a real chance that the epidemic could become a true pandemic and trigger a global recession.

Multiple companies are racing to develop drugs or vaccines that could contain the spread of the current coronavirus strain and COVID-19, the disease caused by the virus. None, though, is in as strong of a position to succeed as Gilead Sciences (NASDAQ:GILD) is. And as crazy as it might sound, Gilead just might prevent a global recession.

Image source: Getty Images.

The first assumption with my premise is that the coronavirus could actually spark a global recession. Don't take my word for it, though. Consider an analysis performed by the Congressional Budget Office (CBO) in 2005 and 2006.

Fifteen years ago, it wasn't the current strain of coronavirus that was worrying governments and investors. Instead, it was the avian flu. Bill Frist, the Senate majority leader at the time, requested that the CBO conduct a study to evaluate the possible macroeconomic impact of an avian flu pandemic.

The CBO determined that a severe avian flu pandemic could cause U.S. gross domestic product (GDP) to fall by around 4.25%. That's more than enough to throw the U.S. into an economic recession. As the U.S. goes, so goes the rest of the world.

Keep in mind that at the beginning of 2006, there had been 142 cases worldwide of avian flu with 74 deaths. So far, there have been over 80,000 cases of the coronavirus across the world with more than 2,700 deaths. It stands to reason that the CBO's analysis related to the avian flu is applicable for the coronavirus -- and the negative economic impact could be even worse.

Major companies are already feeling the effects of the viral outbreak. Applestated last week that it will miss its revenue guidance for the first quarter of 2020 because of the coronavirus. Mastercardreduced its Q1 revenue guidance as a result of the impact that the coronavirus is having on travel. Dun & Bradstreet estimates that at least 51,000 companies across the world will be negatively affected by the virus, including 163 members of the Fortune 1000.

All of this negativity could be a moot point if a safe and effective treatment or vaccine for the virus becomes available. That's where Gilead Sciences enters the picture.

Gilead originally developed experimental antiviral drug remdesivir to treat the Ebola virus. While the drug wasn't as effective as hoped with treating Ebola, it showed promise in preclinical testing in treating two other viruses -- MERS and SARS. Both MERS and SARS are members of the coronavirus family and are similar in structure to the2019-nCoV strain of coronavirus that's causing concerns now.

Over the past four weeks, Gilead has initiated two clinical studies in China evaluating patients with COVID-19. It began a U.S. clinical study earlier this week. The biotech is also working with government and non-government organizations to supply remdesivir to COVID-19 patients as an emergency treatment.

Other drugmakers are also scrambling to test experimental drugs and vaccines. They range from big pharma companies including AbbVie, GlaxoSmithKline, and Johnson & Johnsonto small biotechs such as Inovio, Moderna, and Novavax.

But there's one clear leader at this point -- Gilead. World Health Organization (WHO) assistant director-general BruceAylward stated in a press conference earlier this week that "there is only one drug right now that we think may have real efficacy and that's remdesivir."

Gilead expects to report results from its clinical studies ofremdesivir in April. If those results are positive, expect countries across the world to want the antiviral drug even before any regulatory approvals are granted. Gilead has already ramped up its production efforts and is keeping governments updated on its progress.

It's quite possible that the global economy could hinge on how the clinical studies forremdesivir turn out. Overwhelmingly positive results could enable governments and investors to breathe a huge collective sigh of relief if the drug demonstrates the potential to effectively treat COVID-19 and contain the economic impact of the coronavirus.

Gilead Sciences could end up being a hero to the rescue. But while the biotech stock has jumped on the news of its progress withremdesivir, Gilead might not enjoy as big of a hero's reward as you might think.

Bank of America analyst Geoff Meacham projects that Gilead would likely generate at most $2.5 billion in revenue from its antiviral drug. That's a lot of money, but it represents only around 11% of Gilead's current total revenue and would only give the company a temporary boost.

Gilead just might prevent a global recession. For investors, though, the biotech's HIV franchise and promising immunology drug filgotinib that could win FDA approval later this year are better reasons to consider buying the stock than its coronavirus drug is.

Read more from the original source:
Meet the Company That Just Might Prevent a Global Recession - Motley Fool

Breakthrough research may lead to improved therapeutic options for people with asthma – News-Medical.net

Researchers from Trinity College Dublin have made a breakthrough that may eventually lead to improved therapeutic options for people living with asthma. The researchers have uncovered a critical role for a protein (Caspase-11), which had previously never been implicated in the disease.

They report their findings today [Wednesday 26th February 2020] in leading journal Nature Communications.

Lead author Zbigniew Zaslona, working with a team led by Luke O'Neill, Professor of Biochemistry in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute, has been exploring the role that inflammation plays in asthma - a very common and often serious disease of childhood.

Ireland has one of the highest incidences of asthma in Europe, which in its most severe form remains difficult to treat and can be fatal. Caspase-11 is a protein with an important role in defending against bacteria, but the team in Trinity has found that when it is over-active it can provoke a damaging inflammatory reaction. When this happens, it is likely to be a key driver of allergic inflammation in the lungs of asthmatics.

Dr. Zaslona said:

Caspase-11 can cause cells to die, which is a very inflammatory event as the cells then release their contents, which can irritate tissues in our body. We have found that Caspase-11 is a key driver of inflammation in the airways in asthma. This causes the signs and symptoms of asthma which most notably involves difficulty breathing."

Although symptoms of mild asthma can be managed with current therapies, severe asthma remains very difficult to treat and asthma rates are constantly on the rise.

Dr. Zaslona added:

A variety of irritants such as airborne pollutants, certain types of pollen and house dust mites can induce cell death in the lungs. Our work suggests that Caspase-11 is sensing these noxious things and causing disease."

Professor O'Neill said:

Caspase-11 - or it's human equivalent, which is Caspase-4 - has never been implicated in asthma before so we think it holds great promise as a possible target for new drugs to treat this common, debilitating disease."

Source:

Journal reference:

Zasona, Z., et al. (2020) Caspase-11 promotes allergic airway inflammation. Nature Communications. doi.org/10.1038/s41467-020-14945-2.

Posted in: Medical Science News | Medical Research News | Medical Condition News

Tags: Asthma, Bacteria, Biochemistry, Breathing, Cell, Cell Death, Drugs, Immunology, Inflammation, Lungs, Mites, Protein, Research

See the rest here:
Breakthrough research may lead to improved therapeutic options for people with asthma - News-Medical.net

TLR2 could be targeted to treat age-related macular degeneration – Drug Target Review

Scientists have implicated toll-like receptor 2 (TLR2) in age-related macular degeneration and shown that knocking it out can improve symptoms in animal models.

Researchers have shown that toll-like receptor 2 (TLR2) may play a role in age-related macular degeneration (AMD), the most common cause of central-vision blindness in adults. The scientists suggest targeting TLR2 in the eye may be a future therapy for AMD.

The paper, published in Cell Reports, stated that AMD is associated with two biological processes; uncontrolled oxidative stress resulting in the formation of a bleach-like chemical in the retina and the tagging of cell contents with complement protein. These tags signal for the elimination of the cell contents.

The scientists suggest in this paper that these two processes are linked by TLR2. Found on cell surfaces, TLR2 recognises chemical signals from bacterial infections in the environment outside the cell and activates the immune system.

In the case of the eye, TLR2 appears to act as a sensor of oxidative-stress, recognising a chemical pattern that is generated during oxidation, rather than infection and triggering a signal cascade that ends in promoting the laying down of complement, explained first author on the paper, Dr Kelly Mulfaul, from Trinity College Dublin, Ireland.

Dr Sarah Doyle, study leader and assistant professor of immunology at Trinity, said: A function for TLR2 has not previously been reported in retinal neurodegenerative disease pathology but it is likely to play an important role, because when we remove TLR2 from our experimental model systems we reduce the level of complement and this has the effect of protecting cells that are essential for vision from dying.

With the continual increase in life expectancy outpacing the rate at which drugs for age-related conditions are developed new avenues of therapy are badly needed, so the fact that blocking this single protein can have such a protective effect in the eye is a particularly exciting discovery.

See the rest here:
TLR2 could be targeted to treat age-related macular degeneration - Drug Target Review

Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market – Press Release – Digital Journal

The Humanized Mouse Model Market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period.

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 02/24/2020 -- The key factors propelling the growth of the market are the increasing number of research activities involving humanized models, growing demand for personalized medicine, an increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors. The objective of the report is to define, describe, and forecast the humanized mouse model market size based on type, application, end-user, and region.

According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets.

The Humanized Rat Model market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Market Segmentation in Detailed:

Based on type, the market is segmented into a humanized mouse and humanized rat. The Humanized mouse model market is further segmented into a cell-based and genetic-based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, the study of drug metabolism and disposition, and investigation of immune system development and function.

Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The CROs segment is estimated to register the highest CAGR during the forecast period due to the growth in the number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Worldwide Geographical Analysis:

The North American region is leading the humanized mouse models market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

Major Key Players Operating in Industry:

The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

For more information on this press release visit: http://www.sbwire.com/press-releases/release-1278836.htm

Read the original:
Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market - Press Release - Digital Journal

Infectious Immunology Market Overview and Forecast up to 2019 2027 – Jewish Life News

According to a report published by TMR market, the Infectious Immunology economy is expected to witness a CAGR growth of XX% within the forecast period (2019-2029) and reach at a value of ~US$ at the ending of 2029. The macro-economic and micro elements which are predicted to influence the trajectory of this market are studied in the presented market study.

Light on the raw material throws Suppliers, vendors, manufacturers, and market consumers at the markets value chain. Furthermore, the political and economic scenarios of regions and its effect on the Infectious Immunology market are discussed within the accounts.

Critical Insights enclosed from this report:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=2929

Competitive Outlook

Light onto the throws Business prospects of prominent players operating from the Infectious Immunology sector. The item pricing plans, marketing stations that were preferred , product portfolio of most players, and promote presence of each and every company is contained in the report. The dominant players covered in the report include Business, Business two, Business 3, and Company 4.

Regional Assessment

The presented market study sheds light on the Marketplace Scenario in various markets. Furthermore, the governmental and regulatory policies to the prospects of the Infectious Immunology market in each regions effect is analyzed in the report.

market segments, major geographies, and current market trends. Geographies analyzed under this research report include

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porters five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Excerpt from:
Infectious Immunology Market Overview and Forecast up to 2019 2027 - Jewish Life News

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting – GlobeNewswire

REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology. The presentations will take place at the 2020 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting being held in Philadelphia, Pa. from March 13 to 16, 2020.

Oral Presentations:

Featured Poster Presentations:

Poster Presentations:

Following the presentations, the posters will be available on the Allakos website.

About Allakos Allakosis a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab (AK002) has been tested in five clinical studies. In these studies, antolimab (AK002) eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's websiteat http://www.allakos.com

Source: Allakos Inc.

See the original post here:
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting - GlobeNewswire

Harvard Scientists to Collaborate with Chinese Researchers to Improve Diagnostics and Develop Novel Coronavirus Therapies | News – Harvard Crimson

A team of Harvard scientists will collaborate with a Chinese research institute in a five-year effort to study the novel coronavirus, which has infected more than 78,000 people worldwide, according to a University press release Monday.

Co-led by Harvard Medical School Dean George Q. Daley and Zhong Nanshan the head of an expert team within Chinas National Health Commission that is investigating the outbreak the partnership will focus on creating more accurate diagnostic tests and designing vaccines, antiviral therapies, and treatments. Members of the group have held two video chats since its formation to begin the partnership, according to University spokesperson Jason A. Newton.

According to the press release, Daley said that the Medical School is uniquely positioned to bring together experts in virology, infectious diseases, structural biology, pathology, vaccine development, epidemiology, and public health for the project.

Harnessing our science to tackle global health challenges is at the very heart of our mission as an institution dedicated to improving human health and well-being worldwide, he said in the release.

The two research partners will share $115 million in funding from China Evergrande Group, a real estate giant and Fortune Global 500 company.

Zhong gained international recognition for his work combatting the 2003 Severe Acute Respiratory Syndrome outbreak. He was also the first scientist to publicly confirm human-to-human transmissibility during 2019s n-Cov epidemic.

We are extremely encouraged by the generous gesture from Evergrande to coordinate and support the collaboration and by the overwhelmingly positive response from our Harvard colleagues, Zhong said in the press release.

We look forward to leveraging each of our respective strengths to address the immediate and longer-term challenges and a fruitful collaboration to advance the global well-being of all people, he added.

Hui Ka Yan, who chairs China Evergrande Group, said in the press release that the company is honored to work to stop the outbreak. The groups CEO, Xia Haijun, visited University President Lawrence S. Bacow in Cambridge last Wednesday, according to a statement from the company.

Evergrande is honored to have the opportunity to contribute to the fight against this global public health threat, Hui Ka Yan said in Harvards press release. We thank all the scientists who responded so swiftly and enthusiastically from the Harvard community and are deeply moved by Harvard and Dr. Zhongs teams dedication and commitment to this humanitarian cause. We have the utmost confidence in this global collaborative team to reach impactful discoveries against the outbreak soon.

Bacow said in the release that the collaborators are confident that their work will contribute valuable discoveries to broader global efforts to combat coronavirus.

We are grateful for Evergrandes leadership and generosity in facilitating this collaboration and for all the scientists and clinicians rising to the call of action in combating this emerging threat to global well-being, he said.

Harvard affiliates participating in the effort include Daley; Medical School Dean for Research Operations and Global Programs David E. Golan; Immunology department chair Arlene H. Sharpe; Medicine professor Bruce D. Walker; Harvard School of Public Health Center for Communicable Disease Dynamics director Marc Lipsitch; and Lindsey R. Baden, the director of clinical research in Brigham and Womens Hospitals Division of Infectious Diseases.

Staff writer Michelle G. Kurilla can be reached at michelle.kurilla@thecrimson.com. Follow her on Twitter @MichelleKurilla.

Staff writer Ruoqi Zhang can be reached at ruoqi.zhang@thecrimson.com. Follow him on Twitter @RuoqiZhang3.

See the rest here:
Harvard Scientists to Collaborate with Chinese Researchers to Improve Diagnostics and Develop Novel Coronavirus Therapies | News - Harvard Crimson

Basic Immunology | The IBD Immunologist

The immune system, defined in the simplest terms, is the system in our bodies that defends us against infectious disease. However, our immune systems are far more complex. Not only does it defend us against pathogens, it is also responsible for protecting us against cancer, initiating allergy symptoms, and determining the state of our general health.

The Immune system itself is like a miniature world in our bodies, and it is populated with various immune cells that are supported by the cells making up the tissues and organs of the body. Each type of immune cell has its own specialized function. Some are good at fighting infectious bodies hand to hand like soldiers, while others are specialized at scouting, intelligence and recruitingother cell types during battle. During an immune response, the cells of the surrounding tissues also play their roles and, much like civilians in war, they fight, warn others, or die as a result of the battles.

I will do my best to introduce you to this exciting world in simple terms.

To put it quite simply, the Immune System is designed to protect you. Immunologist refer to the body often as self. This includes all the products of the body ranging from your tissues to the smallest secreted molecules. Life forms and molecules that interact with your body are considered non-self. The non-self life forms are parasites, bacteria and viruses as well as friendly intestinal bacteria. Common non-self molecules that we often encounter are food, pollen and chemical substances from our environments (like drugs, cleaning products and hygienic products)1.

Cells of the immune system are born from hematopoietic stem cells found deep in the bone marrow. Hematopoietic stem cells are immortal, capable of generating daughter cells, called progenitors that will later give rise to different type of immune cells. There are two main types of progenitors created, the myeloid progenitors and the lymphoid progenitors2.

Cells of Myeloid Progenitors

For immunologists, the mammalian body is divided into three main regions: the primary lymphoid areas, the secondary lymphoid areas and the periphery.

The primary lymphoid areas include the bone marrow and the thymus. The bone marrow, as we mentioned, is the site of immune cell generation2. The thymus, on the other hand, is the location of T cell development4. Lymphoid progenitor populations travel there from the bone marrow and produce a population of immature thymocytes. It is these thymocytes that give rise to the varied T cell populations.

The secondary lymphoid areas include the adenoids, tonsils, spleen, lymph nodes and lymphoid follicles found in the gastrointestinal system and the mucosa (areas adjacent to a mucus membrane). These areas house lymphocytes and support the development of an adaptive immune responses5-7.

The periphery includes all regions that are not included in the primary and secondary lymphoid areas. This includes areas like the skin, brain, joints, muscles and gastrointestinal/mucosal areas surrounding lymphoid follicles.

In order for an immune response to be initiated, there must be some kind of danger. This is a fairly simple idea, but it leads to the question: How is danger defined by the immune system? This question is actually one of the most exciting topics of immunology today. Simply put, danger is sensed by the immune system through two main avenues: the recognition of a pathogen-associated molecular pattern (PAMP)8 or through the release of cell molecules associated with trauma which are called danger-associated molecular patterns (DAMPs) or alarmins9. Examples of PAMPs would be cell wall lipoproteins of bacteria and an example of DAMPs would be ATP (adenosine triphosphate), a nucleotide used as an energy source in cells10.

PAMPs and DAMPs are recognized by the cells of the immune system and non-immune cells, through receptors located at the cell surface or internally8,9. PAMPs are also recognized by several non-cellular systems as well11,12. This recognition initiates the very first processes of an immune response called the innate immune response.

Immune cells, non-immune cells and non-cellular systems all participate in initiating an innate immune response. Why is it called innate? Its innate because it depends on intrinsic systems that are built into your body to recognize danger and there is no learning or adaptation involved.

In order to detect PAMPs or DAMPs, cells need tools to recognize them. These tools are protein receptors that can be found on the cell surface as well as internally. In general, they are called pattern recognition receptors or PRRs. These receptors come in families consisting of multiple members. Receptors that recognize PAMPs include the Toll-like receptors (TLRs), the C-type lectin receptors (CLRs), the NOD-like receptors (NLRs), RIG-I-like receptors (RLRs)8 and invariant T cell receptors13,14.

DAMP receptors are not so clear-cut. TLRs have been implicated15 as well as the receptor for advanced glycation endproducts (RAGE)15. Also the purinergic receptors that recognize ATP would also fall into this category10.

These receptors are found on most cells of the body. They recognize a variety patterns associated with a number of pathogens including virus-associated nucleic acids; bacterial-associated cell wall components, protein, ribosomal RNA and DNA; and protozoan-associated proteins8. The majority is found extracellularly, but a number are also found intracellularly. When stimulated they activate the transcription factor NFB, which is essential for activating a cells immune functions and set off a signal cascade via MAP kinase (a phosphorylating enzyme)8.

These receptors are specialized in recognizing carbohydrate structures, such as the sugar mannose, which is a common component of fungal cell walls16. Thus, these receptors are found on the cell surface. Though much of the literature involves their expression on immune cells, reports of CLR variants on non-immune cells can also be found17. On the phagocytic cells, it is known that they can participate in endocytosis, the engulfment of particles or pathogens and respiratory burst16. Some also appear to initiate signal cascades similar to TLRs leading to NFB and MAP kinase activation, but it also appears that they can work in concert with TLRs, enhancing or inhibiting their function16.

These receptors are found in the cytoplasm of cells. Traces of their expression is found in most organs of the body18 and it is probably safe to say that most immune cells express at least some members of the NLR family. These receptors are designed to detect intracellular bacteria and, possibly, endogenous stress molecules and allow the cell to produce one of the most potent inflammatory mediators, Interleukin (IL)-119.

Like NLRs, RLRs are also found in the cytoplasm of a cell. Instead of detecting bacterial products, these receptors help detect viral infection20. They do this by binding to RNA produced during viral replication. Working together with nucleic-acid detecting TLRs, they lead to NFB, MAP kinase activation and activation of Interferon regulatory factor (IRF) transcription factors20. The IRF transcription factors are necessary to produce cytokines specialized for the control of viral infections. Cytokines are small, secreted proteins used as messengers between cells, which alert surrounding immune cells about danger.

Areas of the body that come in contact with the outside world (skin, gastrointestinal and mucosal areas) are covered with an epithelial layer. Epithelial layers are composed mainly of cells called epithelial cells. These cells form an anatomical barrier and they have their own immune functions. When exposed to DAMPs or PAMPs, epithelial cells produce inflammatory cytokines 21. The cells of the epithelial layer are often the main cells involved in the first detection of pathogens and/or danger. The majority of cells in the body also have this capacity. Other cell types like muscle cells, adipocytes and fibroblasts are all outfitted with receptors to detect PAMPs and DAMPs8,22. Just like citizens of a city, they will alert the authorities if there are any problems.

Under epithelial layers are resident macrophages, neutrophils, dendritic cells, NK cells, mast cells and a number of T cell-related cells.

The name macrophage is derived from Greek, meaning large eaters. Their main function is to phagocytize (engulf) pathogens and particles. It does this by wrapping its plasma membrane around particles until they are enveloped and pinched off to form an endosome inside the cell. Once inside the cell, the endosome merges with a lysosome that contains enzymes and acids that can digest the contents. Macrophages also have the ability to generate a respiratory burst, which is a release of oxygen radicals that damage surrounding pathogens and cells. They also can alert and attract other immune cells through inflammatory cytokine release23.

Neutrophils are the main foot soldiers of the innate immune response and are certainly the most abundant. They also have a wide arsenal of tools to deal with invaders. Like macrophages, neutrophils can phagocytize particles, release a respiratory burst and produce inflammatory cytokines. Unlike macrophages, neutrophils have the internal caches of anti-microbial substances called granules24.

Dendritic cells are also phagocytic cells, but they have the special ability of initiating an adaptive immune response (will be discussed later). Unlike neutrophils and macrophages, Dendritic cells or DCs are not simple foot soldiers. Instead, they function more as spies and provide intelligence about invaders to T cells through a phenomenon called antigen presentation and through cytokine production25.

The NK stands for Natural Killer and the name implies their function. These cells, however, do not kill pathogens directly. Instead, these cells have the ability to recognize when other cells are harboring internal pathogens using special receptors and then kill them. Situations where this might occur is during viral and mycobacterial infections. These pathogens easily reside in host cells, finding ways to block lysosome fusion and their own destruction26.

Mast cells are the cells that are responsible for the classic signs of inflammation, which include redness, swelling and heat. Though well known for their association with allergy, they also can detect PAMPs and DAMPs through receptors and become immunologically active. Mast cells exert their functions mainly through cytokine and granule release. Unlike neutrophils, which release antimicrobial substances, mast cells release histamine and heparin. Histamine is well known for its vasodilator function and ability to allow fluid to leak between cells, causing redness and swelling. It also causes inflammatory itching by triggering neurons (unmyelinated C-fibers) responsible for the itch feeling. Heparin prevents blood coagulation27.

Most T cells are part of the adaptive immune response as they have adaptive T cell receptors (receptors that learn to recognize pathogens). NK T cells and T cells, however, use invariant T cell receptors (receptors that do not rearrange) or semi-invariant T cell receptors and participate in the innate immune response.

NK T cells are similar to the NK cells mentioned above. Not so much in function, but more in how they look. These cells share many of the same surface protein markers. NK T cells, however, do not kill compromised cells. Instead, they are quick cytokine producers. In doing so, they quickly notify all surrounding cells that there is problem when they recognize PAMPs presented to them via dendritic cells28.

The T cells are important for innate immune reactions and the adaptive immune response as they have invariant and variant T cell receptors. Their precise function remains unclear, but they can secrete cytokines and, like the NK T cells above, participate in alerting and strengthening local immune responses29.

Besides cells, there are also defenses in your body that are ready to react to pathogens as soon as they are encountered, much like booby traps. These systems rely on small proteins that are found within the bodily fluids.

The liver synthesizes the proteins of the complement system and they work in concert to aid in phagocytosis, bacteria lysing and immune cell attraction. One can visualize it as a self-assembling machine that starts to assemble as soon as the first proteins are bound and in place. The complement machine is known to be initiated by three different pathways: the classical pathway, the alternative pathway and the lectin pathway. The classical pathway is triggered when antibodies are bound to a pathogen. The alternative pathway is triggered when the victim is unable to block the cascade (normal cells can, while pathogens cannot). The lectin pathway uses free lectin proteins (lectins are proteins that bind sugars) to bind sugars associated with bacterial cell walls)11.

These proteins are also produced by the liver and especially during inflammation when pro-inflammatory cytokines are produced. Many are designed to coat pathogens and have chemotactic properties (have the ability to attract cells). Some inhibit microbial growth by sequestering iron from the environment. The lectins from the lectin pathway of complement activation are considered acute phase proteins30.

Often called defensins, these peptides function as natural antibiotics and our produced by cells that guard the external surfaces and internal surfaces such as the skin and the gastrointestinal system. In the skin, the main sources are keratinocytes, mast cells, neutrophils, sebocytes and eccine epithelial cells. In the intestines, one of the main producers are the Paneth cells of intestinal crypts31.

The adaptive immune response is what gives individuals long-term immunity to a pathogen after vaccination. Instead of relying on germ-line encoded receptors for the recognition of pathogens like the innate immune system, it depends on the development of receptors that can recognize any unique molecular characteristic of pathogens32. The molecules that can be recognized are called antigens. The classical definition of an antigen is any molecule that can provoke the development of antibodies. A better, and less-confusing, definition is a molecule that can be recognized by the adaptive immune system. The molecules are often protein peptides (small pieces of protein). But, they can also be sugars, lipids and other small molecules under the right circumstances. The main players of the adaptive immune response are the T cells (both T helper cells and cytotoxic T cells) and the B cells.

During the innate immune response, the first steps are taken to initiate an adaptive immune response. The main cells responsible for this step are the DCs that we described earlier25. As we mentioned before, DCs are a phagocytic cell type. This means that they have the ability to engulf pathogens/particles in endosomes and later fuse these vesicles to lysosomes for destruction. The process, however, does not stop here. Instead of just disposing of the pathogen/particle waste, the DC, instead, uses these parts to educate T helper cells about the pathogens. It does this by traveling from the location where it picked up its parcel to the local lymph node, where it finds T helper cells. Once there, it presents the pathogen-associated peptides on its surface using molecules called MHC class II molecules and provides information to T cells about how it should respond using surface molecules called co-stimulatory molecules and cytokines. Educating T helper cells is the first step towards initiating an adaptive immune response.

T helper cells or Th cells are crucial cells in the adaptive immune response and they are characterized by a surface protein called, CD4. They hold the key to initiating the functions of cytotoxic T cells33 and B cells34. Furthermore, they can also increase the efficacy of macrophages23.

Th cells interact with the MHC class II/peptide complexes presented by antigen presenting cells through its receptor, called the T cell receptor (TCR). If a T cell has never before seen antigen, it is called a nave T cell. In this situation, the T cell will need instruction from a professional antigen presenting cells, usually a DC, about how to perform its function. DCs do this through cell surface proteins call co-stimulatory molecules and through cytokine expression. This process is consists of three main signals. The first signal is the antigen recognition; the second signal is co-stimulation and the third cytokine exposure. This whole process is referred to as priming of the nave T cell. Once primed, the T cells begin to divide; a process that is referred to as expansion or proliferation35.

The most important set of co-stimulatory molecules is CD80 or CD86 on the DC and CD28 on the T cells. This second signal is necessary to tell the Th cell that there is a problem. If signal one is given without this second signal, the T cell will assume that the antigen is actually harmless and become non-responsive in a process called anergy36. Only a DC that has encountered a PAMP or another danger signal will express CD80 or CD86 on its surface reassuring the Th cell that there is, indeed, a problem.

Signal three is the secretion of cytokines of the DC. There are several cytokines important for Th cell eduction. They most important ones are IL-4, IL-12, IL-6, TGF and IL-10. Th cells will differentiate into different types of Th cells depending on which cytokines prevail. The main types of Th cells are T helper 1 (Th1) cells, T helper 2 (Th2) cells, T helper 17 (Th17) cells, and induced regulatory T cells (iTreg)35.

Each Th cell subtype has its own unique set of skills. One could almost see differentiation as an occupation. Just like an athlete will choose to develop her body and a scientist will choose to develop her mind. In humans, these choices are reflected at the level of gene transcription and protein expression. The athlete will stimulate muscle growth and the scientist develops the cerebral cortex of the brain. Its the same for Th cell differentiation. The four main subtypes of Th cells are listed. There are, however, rare forms that have been observed that are not listed and Th cells, much like humans, can fall into gray areas between the stereotypes.

The Th1 path is chosen when T cells are exposed to IL-12 during priming. Th1 cells are characterized by the production of the cytokine, interferon- (IFN) and the expression of the master transcription factor, T-bet. Th1 cells are experts at gearing the immune response towards to the control of internal pathogens like viruses and mycobacteria, which reside internally in macrophages. They perform this function by initiating cytotoxic T cell responses, helping macrophages to become more effective, by helping B cells to produce certain types of antibodies. These functions are executed, in part, through IFN exposure, however, some require cell-cell contact and will be explained in more detail later37.

Th2 cells are created during exposure to high amounts of IL-4. This leads to the expression of the Th2-associated master transcription factor, GATA3. Th2 cells are also characterized by the production of IL-4 (indeed, the same cytokine needed to create them). These cells are designed to skew the immune system towards a humoral immune response (antibody response) that can deal with parasite infection. Unfortunately, Th2 responses are also the ones associated with allergy development as well. Th2 cells do their work by effectively helping B cells and encouraging specific forms of antibodies. This is done through a combination of IL-4 exposure and cell-cell interactions37.

The Th17 subtype is the most recently described of the Th subtypes. It is most effective at controlling extracellular bacterial and fungi responses, like those found during intestinal food poisoning or during a yeast infection. Its creation is dictated by the cytokines IL-6 and TGF and this leads to the expression of the master transcription factor, RORt. Th17 cells produce the cytokine IL-17. IL-17 production is one of the main facilitators of their function and it encourages surrounding cells to increase neutrophil migration. Neutrophils are excellent phagocytic cells with many bacterial killing tools38.

To those just learning about the immune system, the existence of the following Th subtype may be confusing. iTreg are designed to counter the functions of other immune cells. Why? The reason is that immune responses are highly damaging to surrounding tissues and, without them, immune responses would spiral out of control.

That said; these cells are induced by DCs when they are exposed to high amounts of IL-10 or TGF. This causes the expression of the master transcription factor, Foxp3. In turn, iTreg produce IL-10 or TGF. IL-10 and TGF are what is called anti-inflammatory cytokines. They have the ability to limit the functions of immune cells. IL-10, for instance, lowers Th1 and Th17 responses and reduces macrophage efficacy. TGF encourages apoptosis (induced death of cells), prevents cell division and lowers phagocytosis39.

Th cells are not the only kind of T cell. Cytotoxic T cells (CTLs), characterized by the surface marker CD8, are not to be missed and are essential for the elimination of viral infections. The function of a CTL is found in its name. Cyto refers to cell and toxic means just how it sounds. These cells are cell toxic and kill other cells. In many ways, they are similar to the NK cells and NK T cells of the innate immune system. However, they do not use invariant receptors to recognize problems in other cells, but instead use an adaptive system.

CTLs, like Th cells, have a TCR. This means that they can detect unique peptides presented to them by other cells. In the case of Th cells, these are MHC class II molecules presented via DCs. In the case of CTLs, they are MHC class I molecules. During an infection, as we earlier mentioned, DCs will travel to the lymph node and present samples of the intruder to the T cells. This is also happens for CTLs. However, despite the presence of all the priming signals, priming will be suboptimal. CTLs need an additional signal, jokingly called the license to kill. This signal is given by a Th1 cell through the production of a cytokine called IL-2, which stimulates CTL expansion; and through an interaction between the Th1 cell and the DC via CD40 on the DC and CD40 ligand on the Th1 cell, which makes the DC more effective at priming CTLs33. Once a CTL is primed and active, it has the ability to kill.

As you can see, CTL activity is highly controlled to ensure that they react only to pathogen-associated peptides. The reason is that MHC class I can be expressed by every cell type in the body. MHC class I on a cell is like a sign advertising the health of the cell. The cell is constantly displaying samples of the proteins its making. If an active CTL recognizes one of these samples as being of viral origin, it kills that cell; eliminating a viral host.

The word humor means fluid in Latin and, therefore, humoral immune responses relate to non-cellular systems found in the bodily fluids. Weve already discussed non-cellular components of the innate immunity, however, in immunology most people are not referring to these non-cellular systems when they use the term humoral immune response. Instead, they are referring to the immune response mediated by antibodies and this is part of the adaptive immune response.

The cell behind antibody responses is the B cell. Nave B cells of the immune system produce rudimentary antibodies (see below) until other cells activate them. B cells, unlike the T cells, are not required to interact with DCs; instead B cells reside in lymphoid tissues and fish for antigens that they recognize using their B cell receptors or BCR. The BCR looks like a surface bound antibody and once it binds a molecule, the B cell engulfs it and much like the phagocytes, digests it. Just like the DC, the B cell will then present pieces of the antigen to Th cells using MHC class II molecules. Primed and activated Th cells, which recognize the presented peptides, are then able to help the B cell through a CD40-CD40 ligand interaction. The Th cell also provides cytokine signals to tell the B cell which kinds of antibodies it should make34.

This process is reminiscent of the priming process of Th cells. Signal one is the MHC class II/peptide and TCR interaction between the B cell and the T cell. Signal two is the costimulatory help provided by the T cell in the form of CD40-CD40 ligand interactions. And, signal three is the cytokine message provided by the T cell.

Helped B cells will then further differentiates into plasma cells, which can produce massive quantities of antibodies.

Antibodies, by themselves, cause very little harm. However, their strength lies in their ability to tag a molecule as harmful and block molecular functions. Antibodies enhance the functions of the innate immune system. They can bind to pathogens and particles to initiate the complement system and induce phagocytosis. They can also block/neutralize molecular interactions. Examples of this function would be an antibody that blocks the toxic effects of diphtheria toxin or antibodies the block viral binding sites to cells. Antibodies also interact directly with cells and can change their function by binding to specific antibody receptors found on the surfaces of immune cells40.

An Antibody is a small protein structure produced by B cells. It is also called an immunoglobulin (Ig). It looks like a Y and it is formed from four separate proteins. Each tip of the Y recognizes and sticks to the antigen, meaning that each antibody can bind two similar antigens. A single arm is called a Fab (Fragment, antigen binding) fragment. The base of the Y is called the Fc (Fragment constant) region and, while the Fab fragments dictate the specificity of the antigen binding, the Fc region dictates the type of antibody or isotype. The antibody isotype is dictated by the prevalent cytokines in the environment as well as additional danger signals that the B cell experienced while being helped by the Th cell41.

The first types of antibodies that a B cell can produce are IgM and IgD. The M and D refers to different classes of the Fc region. IgM is found as a pentamer, with five individual IgM antibodies bound by their Fc regions in the center forming a star. They are effective at complement activation. IgD is found as a monomer and its function is undefined. However, it has the ability to bind mast cells via an Fc receptor ( for D) and induce anti-microbial peptide secretion.

IgG antibodies are found as monomers and they are very potent at stimulating immune responses. They are capable of neutralization, inducing phagocytosis in macrophages and neutrophils via Fc receptors ( for G), activation of complement, and also the activation of NK cells (also via Fc receptors).

IgE antibodies are monomers. They are known to cause mast cell degranulation via binding of Fc receptors ( for E). They are induced during parasite infection and, unfortunately, also during allergy.

IgA is found as a dimer of two antibodies attached via their Fc regions. It is involved with mucosal defense: found in gastrointestinal system, the respiratory systems. They are particularly effective at neutralization of microbes and toxins.

Once the adaptive immune system has formed a response, the body has a long-term record of the invading pathogen in the form of long-lived plasma cells, memory T cells (not covered here) and antibodies. This is why vaccination is so important. It allows your body to create an adaptive immune response against an invader without having to truly become infected42.

When a body encounters a pathogen for the second time, its a completely different situation than the first encounter. During a second infection, T cells drawn to the inflammation site will have knowledge to help macrophages, recruit more neutrophils, and kill infected cells. Antibodies will be now present to assist complement activation, the phagocytosis of particles, and even kill microbes. The response will be quicker and more effective.

Though separating the two types of responses: innate and adaptive, helps with learning; it can also become an obstacle to seeing the immune response as a complex, dynamic system. It is important when looking at an immunological problem to consider the hosts previous history as it has so much influence on the immune response.

It is my sincere wish that this basic immunology overview helps with your understanding of the immune system. Keep in mind, that it is simplistic (skipping whole areas of immunological interest at times) and I have avoided adding too much terminology. If there are aspects that are particularly confusing, dont hesitate to mention them and I will do my best to update this document.top

1. Tauber, A. I. A. The immune self: theory or metaphor? Immunol Today 15, 134136 (1994).

2. Baldridge, M. T., King, K. Y. & Goodell, M. A. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 32, 5765 (2011).

3. Wu, L. & Liu, Y.-J. Development of Dendritic-Cell Lineages. Immunity 26, 1010 (2007).

4. Anderson, G. & Takahama, Y. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol 33, 256263 (2012).

5. Girard, J.-P., Moussion, C. & Frster, R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12, 762773 (2012).

6. Koboziev, I., Karlsson, F. & Grisham, M. B. Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation. Annals of the New York Academy of Sciences 1207 Suppl 1, E8693 (2010).

7. Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat Rev Immunol 5, 606616 (2005).

8. Takeuchi, O. & Akira, S. Pattern Recognition Receptors and Inflammation. Cell 140, 805820 (2010).

9. Hirsiger, S., Simmen, H.-P., Werner, C. M. L., Wanner, G. A. & Rittirsch, D. Danger Signals Activating the Immune Response after Trauma. Mediators Inflamm. 2012, 110 (2012).

10. Yao, Y., Levings, M. K. & Steiner, T. S. ATP conditions intestinal epithelial cells to an inflammatory state that promotes components of dendritic cell maturation. Eur. J. Immunol. (2012).doi:10.1002/eji.201142213

11. Fujita, T., Matsushita, M. & Endo, Y. The lectin-complement pathwayits role in innate immunity and evolution. Immunol Rev 198, 185202 (2004).

12. Tarr, A. W., Urbanowicz, R. A. & Ball, J. K. The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses 4, 127 (2012).

13. Le Bourhis, L. et al. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol 32, 212218 (2011).

14. Juno, J. A., Keynan, Y. & Fowke, K. R. Invariant NKT Cells: Regulation and Function during Viral Infection. PLoS Pathog 8, e1002838 (2012).

15. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R. & Coyle, A. J. HMGB1 and RAGE in Inflammation and Cancer. Annu. Rev. Immunol. 28, 367388 (2010).

16. Hardison, S. E. & Brown, G. D. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol 13, 817822 (2012).

17. Weng, L. et al. Isolation and characterization of chondrolectin (Chodl), a novel C-type lectin predominantly expressed in muscle cells. Gene 308, 2129 (2003).

18. Lech, M., Avila-Ferrufino, A., Skuginna, V., Susanti, H. E. & Anders, H. J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 22, 717728 (2010).

19. Rubino, S. J., Selvanantham, T., Girardin, S. E. & Philpott, D. J. Nod-like receptors in the control of intestinal inflammation. Current Opinion in Immunology 24, 398404 (2012).

20. Ireton, R. C. & Gale, M., Jr RIG-I Like Receptors in Antiviral Immunity and Therapeutic Applications. Viruses 3, 906919 (2011).

21. Artis, D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8, 411420 (2008).

22. Drouet, M., Dubuquoy, L., Desreumaux, P. & Bertin, B. Visceral fat and gut inflammation. Nutrition 28, 55 (2012).

23. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11, 723737 (2011).

24. Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6, 173182 (2006).

25. Coombes, J. L. & Powrie, F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8, 435446 (2008).

26. Sun, J. C. & Lanier, L. L. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol 11, 645657 (2011).

27. Abraham, S. N. & John, A. L. S. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10, 440452 (2010).

28. Godfrey, D. I., Stankovic, S. & Baxter, A. G. Raising the NKT cell family. Nat Immunol 11, 197206 (2010).

29. Kronenberg, M. & Havran, W. L. Frontline T cells: T cells and intraepithelial lymphocytes. Immunol Rev 215, 57 (2007).

30. Baumann, H. & Gauldie, J. The acute phase response. Immunol. Today 15, 7480 (1994).

31. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Publishing Group 3, 238250 (2005).

32. Boehm, T. Design principles of adaptive immune systems. Nat Rev Immunol 11, 307317 (2011).

33. Behrens, G. et al. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 82, 8490 (2004).

34. Cerutti, A., Puga, I. & Cols, M. New helping friends for B cells. Eur. J. Immunol. 42, 19561968 (2012).

35. Wilson, C. B., Rowell, E. & Sekimata, M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9, 91105 (2009).

Go here to read the rest:
Basic Immunology | The IBD Immunologist